162 related articles for article (PubMed ID: 29448055)
1. Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies.
Dom M; Offner F; Vanden Berghe W; Van Ostade X
J Proteomics; 2018 May; 179():17-29. PubMed ID: 29448055
[TBL] [Abstract][Full Text] [Related]
2. Identification and quantitative analysis of cellular proteins affected by treatment with withaferin a using a SILAC-based proteomics approach.
Narayan M; Seeley KW; Jinwal UK
J Ethnopharmacol; 2015 Dec; 175():86-92. PubMed ID: 26392330
[TBL] [Abstract][Full Text] [Related]
3. SILAC-based quantitative MS approach reveals Withaferin A regulated proteins in prostate cancer.
Kumar R; Nayak D; Somasekharan SP
J Proteomics; 2021 Sep; 247():104334. PubMed ID: 34298187
[TBL] [Abstract][Full Text] [Related]
4. Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo.
Yang H; Wang Y; Cheryan VT; Wu W; Cui CQ; Polin LA; Pass HI; Dou QP; Rishi AK; Wali A
PLoS One; 2012; 7(8):e41214. PubMed ID: 22912669
[TBL] [Abstract][Full Text] [Related]
5. Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells.
Xia S; Miao Y; Liu S
Biochem Biophys Res Commun; 2018 Sep; 503(4):2363-2369. PubMed ID: 29966656
[TBL] [Abstract][Full Text] [Related]
6. Withaferin A-mediated apoptosis in breast cancer cells is associated with alterations in mitochondrial dynamics.
Sehrawat A; Samanta SK; Hahm ER; St Croix C; Watkins S; Singh SV
Mitochondrion; 2019 Jul; 47():282-293. PubMed ID: 30685490
[TBL] [Abstract][Full Text] [Related]
7. Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis.
Li L; Niu B; Zhang W; Hou L; Zheng Y
Acta Biochim Pol; 2022 Mar; 69(1):197-203. PubMed ID: 35235278
[TBL] [Abstract][Full Text] [Related]
8. Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis.
Zhou X; Wu D; Zhu L; Li R; Yu H; Li W
Curr Cancer Drug Targets; 2024; 24(5):534-545. PubMed ID: 38804345
[TBL] [Abstract][Full Text] [Related]
9. The Role of Forkhead Box Q1 Transcription Factor in Anticancer Effects of Withaferin A in Breast Cancer.
Kim SH; Singh KB; Hahm ER; Singh SV
Cancer Prev Res (Phila); 2021 Apr; 14(4):421-432. PubMed ID: 33509807
[TBL] [Abstract][Full Text] [Related]
10. RNA-seq reveals novel cancer-selective and disease subtype-independent mechanistic targets of withaferin A in human breast cancer cells.
Hahm ER; Kim SH; Singh KB; Singh SV
Mol Carcinog; 2021 Jan; 60(1):3-14. PubMed ID: 33150660
[TBL] [Abstract][Full Text] [Related]
11. Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of β-tubulin.
Antony ML; Lee J; Hahm ER; Kim SH; Marcus AI; Kumari V; Ji X; Yang Z; Vowell CL; Wipf P; Uechi GT; Yates NA; Romero G; Sarkar SN; Singh SV
J Biol Chem; 2014 Jan; 289(3):1852-65. PubMed ID: 24297176
[TBL] [Abstract][Full Text] [Related]
12. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis.
Tang Q; Ren L; Liu J; Li W; Zheng X; Wang J; Du G
Cell Prolif; 2020 Jan; 53(1):e12706. PubMed ID: 31642559
[TBL] [Abstract][Full Text] [Related]
13. Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells.
Wang HC; Hu HH; Chang FR; Tsai JY; Kuo CY; Wu YC; Wu CC
Phytomedicine; 2019 Feb; 53():213-222. PubMed ID: 30668401
[TBL] [Abstract][Full Text] [Related]
14. Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.
Hahm ER; Lee J; Abella T; Singh SV
Mol Carcinog; 2019 Nov; 58(11):2139-2148. PubMed ID: 31441116
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells.
Szarc vel Szic K; Op de Beeck K; Ratman D; Wouters A; Beck IM; Declerck K; Heyninck K; Fransen E; Bracke M; De Bosscher K; Lardon F; Van Camp G; Vanden Berghe W
PLoS One; 2014; 9(2):e87850. PubMed ID: 24498382
[TBL] [Abstract][Full Text] [Related]
16. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes.
Grover A; Shandilya A; Bisaria VS; Sundar D
BMC Genomics; 2010 Dec; 11 Suppl 4(Suppl 4):S15. PubMed ID: 21143798
[TBL] [Abstract][Full Text] [Related]
17. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry".
Yang H; Shi G; Dou QP
Mol Pharmacol; 2007 Feb; 71(2):426-37. PubMed ID: 17093135
[TBL] [Abstract][Full Text] [Related]
18. Cytoprotective autophagy induction by withaferin A in prostate cancer cells involves GABARAPL1.
Hahm ER; Singh SV
Mol Carcinog; 2020 Oct; 59(10):1105-1115. PubMed ID: 32743846
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells.
Li X; Zhu F; Jiang J; Sun C; Zhong Q; Shen M; Wang X; Tian R; Shi C; Xu M; Peng F; Guo X; Hu J; Ye D; Wang M; Qin R
Autophagy; 2016 Sep; 12(9):1521-37. PubMed ID: 27308733
[TBL] [Abstract][Full Text] [Related]
20. Autophagy fails to alter withaferin A-mediated lethality in human breast cancer cells.
Hahm ER; Singh SV
Curr Cancer Drug Targets; 2013 Jul; 13(6):640-50. PubMed ID: 23607597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
